Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. imūnsistēmas sākums ir pierādīts 1 nedēļu pēc primārās vakcinācijas kursa rinotraheīta, kalicivīrusa un chlamydophila felis sastāvdaļu. imunitātes ilgums ir 1 gads pēc pēdējās (atkārtotas) vakcinācijas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. imūnsistēmas sākums ir pierādīts vienu nedēļu pēc primārās vakcinācijas kursa rinotraheīta, kalicivīrusa, chlamydophila felis un panleikopēnijas sastāvdaļām. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

genera inc., horvātija - novājinātu dzīvu vīrusu putnu infekcijas, bronhīts, massachusetts serotipa, pamatcelma h-120 - liofilizāts okulonazālas suspensijas pagatavošanai/lietošanai ar dzeramo ūdeni - vistas

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vakcīnas - infanrix penta ir indicēts primārai un revakcinācijai zīdaiņiem pret difteriju, stingumkrampjiem, garā klepus, b hepatītu un poliomielītu.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

ceva sante animale., francija - kabergolīns - šķīdums iekšķīgai lietošanai - 50 µg/ml - suņi

Latvija - latviešu - Zāļu valsts aģentūra

n.v. organon, netherlands - mometazona furoāts - deguna aerosols, suspensija - 50 µg/devā

Latvija - latviešu - Zāļu valsts aģentūra

boehringer ingelheim international gmbh, germany - ipratropii bromidum, fenoteroli hydrobromidum - aerosols inhalācijām, zem spiediena, šķīdums - 20/50 mikrogrami/devā